Skip to main content Skip to main navigation menu Skip to site footer
International Journal of Nutrology
Case Report
DOI: 10.54448/ijn22304
Submitted: 30-09-2022
Published: 30-09-2022

Pseudohipoaldosteronism Type 1: a case report supported by a literature review

UNIMAR - University of Marilia, Faculty of Medicine, Marilia, Sao Paulo, Brazil
UNIMAR - University of Marilia, Faculty of Medicine, Marilia, Sao Paulo, Brazil
FAMEMA - Faculty of Medicine of Marília, Marilia, Sao Paulo, Brazil
UNIMAR - University of Marilia, Faculty of Medicine, Marilia, Sao Paulo, Brazil
FAMEMA - Faculty of Medicine of Marília, Marilia, Sao Paulo, Brazil
FAMEMA - Faculty of Medicine of Marília, Marilia, Sao Paulo, Brazil
ICR Volunteer - Children's Institute of Hospital das Clínicas da FMUSP, Sao Paulo, Brazil, and volunteer University of Marília-Unimar, Marilia, Sao Paulo, Brazil
UNIMAR - University of Marilia, Faculty of Medicine, Marilia, Sao Paulo, Brazil
UNIMAR - University of Marilia, Faculty of Medicine, Marilia, Sao Paulo, Brazil
UNIMAR - University of Marilia, Faculty of Medicine, Marilia, Sao Paulo, Brazil / CENID - Interdisciplinary Center for Diabetes, Marilia, Sao Paulo, Brazil
Pseudohypoaldosteronism type 1 Hyponatremia Hyperkalemia

Abstract

In the neonatal period, hydro electrolytic disorders with dehydration and metabolic acidosis can cause admission to an intensive care unit and become a diagnostic challenge. Among such disorders, hyponatremia and hyperkalemia become diagnostic challenges with hormonal involvement, including aldosterone. Pseudohypoaldosteronism (PHA) resulting from the lack of response to aldosterone in target cells can be classified into three types and its suspected diagnosis in cases of hyponatremia, hyperkalemia with an elevation of serum aldosterone, can be confirmed by exome sequencing with identification of a potentially pathogenic. This study was based on the case report of a newborn of consanguineous parents who, after birth, evolved in the first week of life with shock, hyponatremia, hyperkalemia, and metabolic acidosis. An initial investigation ruled out congenital adrenal hyperplasia. The presence of hyperaldosteronism with increased plasma renin activity, associated with hyperkalemia and hyponatremia difficult to control with electrolyte replacement, led to a molecular investigation that confirmed PHA type 1 by a mutation in the SCCN1A gene. In neonates with severe hyponatremia that is difficult to resolve with conventional treatment and elevation of serum aldosterone, this pathology must be remembered and investigated, avoiding high morbidity and mortality.

Metrics

Metrics Loading ...

References

  1. Gromotowicz-Poplawska A, Szoka P, Kolodziejczyk P, Kramkowski K, Wojewodzka-Zelezniakowicz M, Chabielska, E. New agents modulating the renin-angiotensin-aldosterone system—Will there be a new therapeutic option?. Experimental Biology and Medicine, 2016, 241(17), 1888-1899.
  2. Shibata S. Context-dependent mechanisms modulating aldosterone signaling in the kidney. Clinical and experimental nephrology, 2016, 20(5), 663-670.
  3. Zavatta G, Casadio E, Rinaldi E, Pagotto U, Pasquali R, Vicennati V. Aldosterone and type 2 diabetes mellitus. Hormone molecular biology and clinical investigation, 2016, 26(1), 53-59.
  4. Arai K, Chrousos GP. Aldosterone deficiency and resistance. 2016.
  5. Stowasser M, Gordon RD. Primary aldosteronism: changing definitions and new concepts of physiology and pathophysiology both inside and outside the kidney. Physiological reviews, 2016, 96(4), 1327-1384.
  6. El Ghorayeb N, Bourdeau I, Lacroix A. Role of ACTH and other hormones in the regulation of aldosterone production in primary aldosteronism. Frontiers in endocrinology, 2016, 7, 72.
  7. Vecchiola A, Lagos CF, Carvajal CA, Baudrand R, Fardella CE. Aldosterone production and signaling dysregulation in obesity. Current hypertension reports, 2016, 18(3), 20.
  8. Borghi F, Sevá-Pessôa B, Grassi-Kassisse DM. The adipose tissue and the involvement of the renin–angiotensin–aldosterone system in cardiometabolic syndrome. Cell and tissue research, 2016, 366(3), 543-548.
  9. Rahimi Z. The role of renin angiotensin aldosterone system genes in diabetic nephropathy. Canadian journal of diabetes, 2016, 40(2), 178-183.
  10. Valinsky WC, Touyz RM, Shrier, A. Aldosterone, SGK1, and ion channels in the kidney. Clinical Science, 2018, 132(2), 173-183.
  11. Cat AND, Friederich-Persson M, White A, Touyz RM. Adipocytes, aldosterone and obesity-related hypertension. Journal of molecular endocrinology, 2016, 57(1), F7-F21.
  12. Sabbadin C, Armanini, D. Syndromes that mimic an excess of mineralocorticoids. High Blood Pressure & Cardiovascular Prevention, 2016, 23(3), 231-235.
  13. Perez Maraver M, Estepa Marin A. Hipoaldosteronismo. Medicine - Programa de Formacion Medica Continuada Acreditado. 2004;9(15):923-9.
  14. Manipriya R, Umamaheswari B, Prakash A, Binu N. Rare Cause of Hyperkalemia in the Newborn Period: Report of Two Cases of Pseudohypoaldosteronism Type 1. Indian J Nephrol. 2018;28(1):69-72.
  15. Riepe FG. Clinical and molecular features of type 1 pseudohypoaldosteronism. Horm Res. 2009;72(1):1-9.
  16. Fernandes-Rosa FL, Antonini SR. [Mineralocorticoid resistance: pseudohypoaldosteronism type 1]. Arq Bras Endocrinol Metabol. 2007;51(3):373-81.
  17. Sethi SK, Wazir S, Bansal S, Khokhar S, Wadhwani N, Raina R. Secondary Pseudohypoaldosteronism Masquerading Congenital Adrenal Hyperplasia in a Neonate. Kidney Int Rep. 2018;3(3):752-4.
  18. Choudhry S, Najam Y. Life threatening hyperkalemia in a neonate with pseudohypoaldosteronism. J Pak Med Assoc. 2012;62(3):287-8.
  19. Nephrol. 2018;28(1):69-72.
  20. Casas-Alba D, Vila Cots J, Monfort Carretero L, Martorell Sampol L, Zennaro MC, Jeunemaitre X, et al. Pseudohypoaldosteronism types I and II: little more than a name in common. J Pediatr Endocrinol Metab. 2017; 30(5):597-601.
  21. Miranda Margarida, Fontoura Manuel. Pseudohipoaldosteronismo tipo I na criança. Arq Med [Internet]. 2013 Dez [citado 2018 Set 19]; 27(6): 265-271.
  22. Manikam L, Cornes MP, Kalra D, Ford C, Gama R. Transient pseudohypoaldosteronism masquerading as congenital adrenal hyperplasia. Ann Clin Biochem. 2011; 48(Pt 4):380-2.
  23. Sartorato P, Khaldi Y, Lapeyraque AL, Armanini D, Kuhnle U, Salomon R, et al. Inactivating mutations of the mineralocorticoid receptor in Type I pseudohypoaldosteronism. Mol Cell Endocrinol. 2004; 217(1-2):119-25.
  24. Metz J, Kesper MS, Uetz B, Burdach S, Warncke K. [Transient Pseudohypoaldosteronism - an Important Differential Diagnosis to Congenital Adrenal Hyperplasia]. Klin Padiatr. 2018; 230(4):229-30.
  25. Turan I, Kotan LD, Tastan M, Gurbuz F, Topaloglu AK, Yuksel B. Molecular genetic studies in a case series of isolated hypoaldosteronism due to biosynthesis defects or aldosterone resistance. Clin Endocrinol (Oxf). 2018; 88(6):799-805
  26. Hanukoglu A, Hanukoglu I. Clinical improvement in patients with autosomal recessive pseudohypoaldosteronism and the necessity for salt supplementation. Clin Exp Nephrol. 2010; 14(5):518-9.
  27. Bandhakavi M, Wanaguru A, Ayuk L, Kirk JM, Barrett TG, Kershaw M, Högler W, Shaw NJ. Clinical characteristics and treatment requirements of children with autosomal recessive pseudohypoaldosteronism. Eur J Endocrinol. 2021 May;184(5):K15-K20. doi: 10.1530/EJE-20-0152.

How to Cite

Fernandes, N. C. B., Simensato, D. C. U., Vizzotto, L. J. H., Haber, R. S. de A., Jacob, C. G. F., Sanches, A. S. O., Piazzon, F. B., Agostinho Junior, F., Haber, L. S. de A., & Haber, J. F. dos S. (2022). Pseudohipoaldosteronism Type 1: a case report supported by a literature review. International Journal of Nutrology, 15(3). https://doi.org/10.54448/ijn22304